A new global plan aims to end most cases of polio by late next year, and essentially eradicate the paralyzing disease by 2018 — if authorities can raise the $5.5 billion needed to do the work, health officials said Tuesday. Part of the challenge will be increasing security for vaccine workers who have come under attack in two of the hardest-hit countries. And the plan calls for changing how much of the world protects against polio, phasing out the long-used oral vaccine in favor of a pricier but safer shot version.
The Food and Drug Administration on Friday approved a first-of-its-kind diabetes drug from Johnson & Johnson that uses a new method to lower blood sugar—flushing it out in patients' urine. The agency cleared J&J's Invokana tablets for adults with Type 2 diabetes, which affects an estimated 26 million Americans. The once-a-day medication works by blocking the kidneys from reabsorbing sugar, which occurs at higher levels in patients with diabetes than in healthy patients.
The Food and Drug Administration said Wednesday it approved a new drug from Biogen Idec to control multiple sclerosis in adults with hard-to-treat forms of the disease. The twice-a-day capsules, called Tecfidera, offer a new option for multiple sclerosis, a debilitating disease in which the body attacks its own nervous system.
Shares of drugmaker Amgen Inc. are rising on news its innovative melanoma drug, which uses a virus as a Trojan horse to infiltrate and destroy tumors, shrank far more tumors than a standard treatment in a late-stage test. The results, released late Tuesday, show there's promise for similar vaccines other companies are developing.
The drug-resistant bacteria known as MRSA, once confined to hospitals but now widespread in communities, will likely continue to exist in both settings as separate strains, according to a new study. Researchers at Princeton University used mathematical models to explore what will happen to community and hospital MRSA strains, which differ genetically.
A research team at the National Institute of Materials Science in Japan has recently developed a gel material which is capable of releasing drugs in response to pressure applied by the patient. Three fingers applying force to the site of the gel produces an effect for up to three days. They built the new drug from two materials already used in pharmaceuticals: a saccharide and a natural component of algae.
Most people who are killed by cancer are victims of the spread of the original cancerous tumor, which is why researchers vigorously search for drugs that can prevent metastases. In a finding that could help accelerate that effort, researchers have found a chemical compound that appears to control cell migration and adhesion, two important characteristics of metastatic cancer cells.
The Food and Drug Administration has approved a new imaging drug to help doctors locate lymph nodes in patients with breast cancer and skin cancer. The drug Lymphoseek from Navidea Biopharmaceuticals Inc. is a radioactive imaging agent that is intended to help determine if breast cancer or melanoma has spread to a patient's lymph nodes.
Biogen Idec has filed for federal marketing approval of a longer-lasting treatment for hemophilia A. Biogen says the drug rFVIIIFc can be injected once or twice a week, while other treatments for hemophilia A need to be injected three or four times a week. The drug could be the first major advance in the treatment of hemophilia in more than 20 years.
According to findings by researchers at Washington University School of Medicine in St. Louis, nanoparticles carrying a toxin found in bee venom can destroy human immunodeficiency virus (HIV) while leaving surrounding cells unharmed. The finding is an important step toward developing a vaginal gel that may prevent the spread of HIV, the virus that causes AIDS.
India's patent appeals office has rejected Bayer AG's plea to stop the production of a cheaper generic version of a patented cancer drug in a ruling that health groups say is an important precedent for getting inexpensive lifesaving medicines to the poor. Bayer sells a one month supply of the drug for about $5,600. Natco's version would cost Indian patients $175 a month, less than 1/30th as much.
In systemic lupus erythematosus, the body attacks itself for largely mysterious reasons, leading to serious tissue inflammation and organ damage. Current drug treatments address symptoms only and can require life-long daily use at toxic doses. Now, scientists at Yale University have designed and tested a drug delivery system that uses biodegradable nanoparticles to deliver low drug doses. The method shows early promise for improved treatment of lupus and other chronic, uncured autoimmune diseases.
Many researchers have been investigating the potential of tiny particles filled with drugs to treat cancer. A team of scientists in Sweden have recently made an advance in this area of research by developing “theranostic” nanoparticles, which combine therapy and diagnostics in the same nanomaterial. They are trackable through magnetic resonance.
Bioengineering researchers at University of California, Santa Barbara have found that changing the shape of chemotherapy drug nanoparticles from spherical to rod-shaped made them up to 10,000 times more effective at specifically targeting and delivering anti-cancer drugs to breast cancer cells. The findings could have a big impact on the effectiveness of anti-cancer therapies and reducing the side effects of chemotherapy
Inspired by a chemical that fungi secrete to defend their territory, Massachusetts Institute of Technology chemists have synthesized and tested several dozen compounds that may hold promise as potential cancer drugs.
While studying a mutant strain of yeast, Purdue University researchers may have found a new target for drugs to combat cholesterol and fungal diseases.
French drugmaker Sanofi said Monday the Food and Drug Administration is starting a review of its once-a-day diabetes treatment lixisenatide. Lixisenatide is a treatment for type 2 diabetes in adults. It works by increasing the body's insulin production and is part of a class of drugs called GLP-1 agonists.
Better cancer drugs that zero in on a tumor with fewer side effects. A universal flu vaccine that could fight every strain of influenza without needing a yearly shot. Research into potentially life-saving products like these will be delayed and newer discoveries shelved if Congress can't avert impending budget cuts that the director of the National Institutes of Health warns will have far-reaching effects.
Side effects are a major reason that drugs are taken off the market and a major reason why patients stop taking their medications, but scientists are now reporting the development of a new way to predict those adverse reactions ahead of time. The computer-based approach could save patients from severe side effects and save drug companies time and money.
Chemists at Boston College have designed a new class of catalysts triggered by the charge of a single proton, the team reports in Nature. The simple organic molecules offer a sustainable and highly efficient platform for chemical reactions that produce sets of molecules crucial to advances in medicine and the life sciences.
Cancer researchers from Rice University suggest that a new man-made drug that’s already proven effective at killing cancer and drug-resistant bacteria could best deliver its knockout blow when used in combination with drugs made from naturally occurring toxins.
Biotech giant Amgen Inc. and Belgian drugmaker UCB SA have scrapped plans for late-stage testing of an experimental treatment for accelerated healing of fractures, but will continue testing their drug for a much bigger and potentially lucrative market, treating osteoporosis in postmenopausal women.
Researchers at the University of Michigan's Life Sciences Institute have found that amlexanox, an off-patent drug currently prescribed for the treatment of asthma and other uses, also reverses obesity, diabetes, and fatty liver in mice.
In a promising step against a genetic disease that causes deafness and gradual loss of vision, scientists have partly restored hearing with a single injection to young mice. Experts praised the study on Usher syndrome, but the results are still a long way from preventing the disease.
Drug developer Eli Lilly and Co. is stopping clinical testing of an experimental rheumatoid arthritis treatment because it wasn't working. The Indianapolis company said Thursday it will continue studying the potential drug, tabalumab, as a possible treatment for a form of the autoimmune disorder lupus and the bone marrow cancer multiple myeloma.